Preclinical Efficacy of CD33 Chimeric Antigen Receptor T Cell Immunotherapy in Childhood Acute Myeloid Leukemia

被引：0
|
作者：
Yang, L. [1 ]
Tarun, S. [1 ]
Shen, F. [2 ,3 ]
Qin, H. [1 ]
Chien, C. D. [1 ]
Kohler, M. L. [1 ]
Fry, T. J. [4 ]
Tasian, S. [2 ,3 ]
机构：
[1] NCI, Pediat Oncol Branch, Bethesda, MD 20892 USA
[2] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA
[3] Ctr Childhood Canc Res, Philadelphia, PA USA
[4] Univ Colorado Denver, Pediat Hematol & Immunol, Aurora, CO USA
来源：
PEDIATRIC BLOOD & CANCER | 2018年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O-100
引用
收藏
页码：S55 / S55
页数：1
相关论文
共 50 条
  • [1] Chimeric Antigen Receptor-Modified T Cells for the Treatment of Acute Myeloid Leukemia Expressing CD33
    Song, Degang
    Swartz, Michael H.
    Biesecker, Steve G.
    Borda, Fernando
    Shah, Rutul R.
    Emtage, Peter
    Wierda, William G.
    Cooper, Laurence J. N.
    Chan, Tim
    BLOOD, 2016, 128 (22)
  • [2] Bispecific CD33/CD123 Targeted Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
    Boucher, Justin C.
    Shrestha, Bishwas
    Vishwasrao, Paresh
    Leick, Mark B.
    Nhan Tu
    Ghafoor, Tayyebb
    Reid, Kayla M.
    Spitler, Kristen
    Yu, Bin
    Maus, Marcela, V
    Davila, Marco L.
    BLOOD, 2022, 140 : 10275 - 10276
  • [3] Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia
    Boucher, Justin C.
    Shrestha, Bishwas
    Vishwasrao, Paresh
    Leick, Mark
    Cervantes, Estelle V.
    Ghafoor, Tayyebb
    Reid, Kayla
    Spitler, Kristen
    Yu, Bin
    Betts, Brian C.
    Guevara-Patino, Jose A.
    Maus, Marcela V.
    Davila, Marco L.
    MOLECULAR THERAPY ONCOLYTICS, 2023, 31
  • [4] Checkpoint Blockade in Combination with CD33 Chimeric Antigen Receptor T Cell Therapy and Hypomethylating Agent Against Acute Myeloid Leukemia
    Xue, Tongyuan
    Del Real, Marissa
    Marcucci, Emanuela
    Toribio, Candida
    Setayesh, Sonia Maryam
    Forman, Stephen J.
    Horne, David A.
    Budde, Lihua E.
    BLOOD, 2019, 134
  • [5] Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design
    Qin, Haiying
    Yang, Lila
    Chukinas, John A.
    Shah, Nirali
    Tarun, Samiksha
    Pouzolles, Marie
    Chien, Christopher D.
    Niswander, Lisa M.
    Welch, Anthony R.
    Taylor, Naomi
    Tasian, Sarah K.
    Fry, Terry J.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (09)
  • [6] Preclinical Development of FLT3-Redirected Chimeric Antigen Receptor T Cell Immunotherapy for Acute Myeloid Leukemia
    Chien, Christopher Daniel
    Sauter, Christopher Tor
    Ishii, Kazusa
    Sang Minh Nguyen
    Shen, Feng
    Tasian, Sarah K.
    Chen, Weizao
    Dimitrov, Dimiter S.
    Fry, Terry J.
    BLOOD, 2016, 128 (22)
  • [7] CD33 Directed Chimeric Antigen Receptor T Cell Therapy As a Novel Preparative Regimen Prior to Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia
    Kenderian, Saad S.
    Ruella, Marco
    Shestova, Olga
    Klichinsky, Michael
    Scholler, John
    Song, Decheng
    Porter, David L.
    Carroll, Martin
    June, Carl H.
    Gill, Saar
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (02) : S25 - S26
  • [8] ANTI-CD33 CHIMERIC ANTIGEN RECEPTOR THERAPY FOR ACUTE MYELOID LEUKEMIA
    O'Hear, Carol
    Heiber, Joshua
    Geiger, Terrence
    PEDIATRIC BLOOD & CANCER, 2014, 61 : S1 - S1
  • [9] Anti-CD33 Chimeric Antigen Receptor Therapy For Acute Myeloid Leukemia
    O'Hear, Carol E.
    Heiber, Joshua
    Geiger, Terrence L.
    BLOOD, 2013, 122 (21)
  • [10] Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia
    O'Hear, Carol
    Heiber, Joshua F.
    Schubert, Ingo
    Fey, Georg
    Geiger, Terrence L.
    HAEMATOLOGICA, 2015, 100 (03) : 336 - 344
12345